Study on key genes and regulatory networks associated with osteoporosis by microarray technology

Genetic Testing and Molecular Biomarkers

Volumn 17, Issue 8, 2013, Pages 625-630

  Zhang, Yue Hui ^a   Shen, Lei ^a   Shen, Yun ^a   Chen, Xiao Dong ^a   Jiang, Lei Sheng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; TRANSCRIPTION FACTOR;

AGED; ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; GENE FUNCTION; GENE REGULATORY NETWORK; GENETIC ALGORITHM; GENETIC ASSOCIATION; HUMAN; MOLECULAR GENETICS; PATHOGENESIS; PRIMARY OSTEOPOROSIS; REGULATOR GENE; TRANSCRIPTION REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; OSTEOPOROSIS;

AGED; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; HUMANS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOPOROSIS;

EID: 84881155007     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2013.0055     Document Type: Article

References (27)

1. Abdulameer SA, Sulaiman SA, Hassali MA, et al. (2012) Osteoporosis and type 2 diabetes mellitus: what do we know, and what we can do? Patient Prefer Adherence 6:435-448.
2. Asensi V, Montes AH, Valle E, et al. (2007) The NOS3 (27-bp repeat, intron 4) polymorphism is associated with susceptibility to osteomyelitis. Nitric Oxide 16:44-53.
3. Cummings SR, Kelsey JL, Nevitt MC, et al. (1985) Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 7:178-208.
4. Diab DL, Watts NB (2012) Bisphosphonates in the treatment of osteoporosis. Endocrinol Metab Clin North Am 41:487-506.
5. Farhang-Fallah J, Yin X, Trentin G, et al. (2000) Cloning and characterization of PHIP, a novel insulin receptor substrate-1 pleckstrin homology domain interacting protein. J Biol Chem 275:40492-40497.
6. Gunther Sillero MA, de Diego A, Perez-Zuniga FJ, et al. (2008) Synthesis of bisphosphonate derivatives of ATP by T4 DNA ligase, ubiquitin activating enzyme (E1) and other ligases. Biochem Pharmacol 75:1959-1965.
7. Hasty P, Campisi J, Hoeijmakers J, et al. (2003) Aging and genome maintenance: lessons from the mouse? Science 299:1355-1359.
8. Jergas M (2011) Radiological diagnosis of osteoporosis - assessment of fracture risk. MMW Fortschr Med 153:33-36.
9. Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929-1936.
10. Kitazawa S, Kitazawa R, Obayashi C, et al. (2005) Desmoid tumor with ossification in chest wall: possible involvement of BAMBI promoter hypermethylation in metaplastic bone formation. J Bone Miner Res 20:1472-1477.
11. Li B (2008) Bone morphogenetic protein-Smad pathway as drug targets for osteoporosis and cancer therapy. Endocr Metab Immune Disord Drug Targets 8:208-219.
12. Lin JT, Lane JM (2004) Osteoporosis: a review. Clin Orthop Relat Res 425:126-134.
13. Maire G, Martin JW, Yoshimoto M, et al. (2011) Analysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma. Cancer Genet 204:138-146.
14. Manolagas SC (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115-137.
15. Napoli N, Villareal DT, Mumm S, et al. (2005) Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res 20:232-239.
16. Naruse M, Ishihara Y, Miyagawa-Tomita S, et al. (2002) 3-Methylcholanthrene, which binds to the arylhydrocarbon receptor, inhibits proliferation and differentiation of osteoblasts in vitro and ossification in vivo. Endocrinology 143:3575-3581.
17. Quan J, Yahata T, Tamura N, et al. (2009) Relationship between single nucleotide polymorphisms in CYP1A1 and CYP1B1 genes and the bone mineral density and serum lipid profiles in postmenopausal Japanese women taking hormone therapy. Menopause 16:171-176.
18. Rayalam S, Yang JY, Della-Fera MA, et al. (2011) Novel molecular targets for prevention of obesity and osteoporosis. J Nutr Biochem 22:1099-1104.
19. Silva-Fernandez L, Rosario MP, Martinez-Lopez JA, et al. (2012) Denosumab for the treatment of osteoporosis: a systematic literature review. Reumatol Clin 9:42-52.
20. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, et al. (2009) New sequence variants associated with bone mineral density. Nat Genet 41:15-17.
21. Sun GJ, Guo T, Chen Y, et al. (2013) Significant pathways detection in Osteoporosis based on the bibliometric network. Eur Rev Med Pharmacol Sci 17:1-7.
22. Thrailkill KM, Lumpkin CK, Jr., Bunn RC, et al. (2005) Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab 289:E735-E745.
23. Walsh GM (2012) Treatment options for postmenopausal osteoporosis. Ther Clin Risk Manag 8:367-368.
24. Watanabe K, Hishiya A (2005) Mouse models of senile osteoporosis. Mol Aspects Med 26:221-231.
25. WillingM, SowersM,AronD, et al. (1998) Bone mineral density and its change in white women: estrogen and vitamin D receptor genotypes and their interaction. J Bone Miner Res 13:695-705.
26. Xia J, Zhong Y, Huang G, et al. (2012) The relationship between insulin resistance and osteoporosis in elderly male type 2 diabetes mellitus and diabetic nephropathy. Ann Endocrinol (Paris) 73:546-551.
27. Yamashita M, Ying SX, Zhang GM, et al. (2005) Ubiquitin ligase Smurf1 controls osteoblast activity and bone homeostasis by targeting MEKK2 for degradation. Cell 121:101-113.